^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Nectin-4-targeted antibody-drug conjugate

    Related drugs:
    16h
    Circulating Tumor DNA Response In Urothelial Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Oklahoma | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    4d
    SHR-A2102-212: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=300, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tagrisso (osimertinib) • carboplatin • paclitaxel • SHR-A2102 • AiRuiLi (adebrelimab)
    11d
    A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (clinicaltrials.gov)
    P1/2, N=270, Recruiting, Merck Sharp & Dohme LLC | N=180 --> 270 | Trial completion date: Jan 2028 --> Mar 2031 | Trial primary completion date: Jan 2028 --> Oct 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    MK-3120
    14d
    ENCORE: Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=34, Recruiting, University of Utah | Trial completion date: Sep 2027 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    Padcev (enfortumab vedotin-ejfv)
    15d
    EV-104: A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P1, N=37, Terminated, Astellas Pharma Global Development, Inc. | N=58 --> 37 | Trial completion date: May 2028 --> Sep 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Sep 2025; Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, ethics committee, or institutional review board or EC/IRB.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Padcev (enfortumab vedotin-ejfv)
    17d
    A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MK-3120
    18d
    SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=412, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    docetaxel
    18d
    A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P2 trial
    |
    Tagrisso (osimertinib) • carboplatin • paclitaxel • SHR-A2102 • AiRuiLi (adebrelimab)
    18d
    Clinical and Molecular Predictors of Response and Survival in Patients with Urothelial Carcinoma Treated with Enfortumab Vedotin: A Systematic Review and Meta-analysis. (PubMed, Eur Urol Open Sci)
    We summarize data from published studies to identify factors that influence outcomes for patients with advanced cancer of the urinary tract treated with a drug called enfortumab vedotin. An understanding of these factors can help in personalizing therapy for patients and improving their care.
    Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    PD-L1 expression
    |
    Padcev (enfortumab vedotin-ejfv)
    20d
    Integrin β4 Drives Immune Evasion and Therapeutic Resistance to PD-1 blockade in Bladder Cancer via MEK/ERK Signaling. (PubMed, J Biol Chem)
    Our previous work established that the elevation of ITGB4 in BLCA was closely related to cisplatin resistance...Our research also discovered a positive correlation between ITGB4 and the ADCs drug target NECTIN4, and the overexpression of ITGB4 upregulates BLCA sensitivity to enfortumab vedotin treatment. It provides a basis for the treatment choice of advanced BLCA patients with immunotherapy resistance. Collectively, these results suggest that ITGB4 may be a promising therapeutic target for advanced BLCA.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • ITGB4 (Integrin Subunit Beta 4) • JUN (Jun proto-oncogene)
    |
    cisplatin • Padcev (enfortumab vedotin-ejfv)
    21d
    NECTIN4 amplification as a predictive biomarker for enfortumab vedotin response (PubMed, Pathologie (Heidelb))
    These findings identify NECTIN4 amplification as a stable, predictive biomarker that may guide treatment decisions in mUC. Data from TCGA further suggest a cross-entity relevance of NECTIN4 amplification, supporting future clinical exploration of EV in other solid tumors.
    Clinical • Journal • IO biomarker
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)
    1m
    DAD: Sacituzumab Govitecan Plus EV in Metastatic UC (clinicaltrials.gov)
    P1/2, N=106, Recruiting, Dana-Farber Cancer Institute | Enrolling by invitation --> Recruiting | Trial completion date: May 2026 --> May 2028 | Trial primary completion date: Oct 2025 --> Feb 2027
    Enrollment status • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv)